Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1Other 1Head & Neck 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 1Tongue Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Mucositis 1

Interventions

Cyclophosphamide 626pembrolizumab 505Paclitaxel 456Gemcitabine 439Carboplatin 437Cisplatin 420Radiotherapy 382fludarabine 367Nivolumab 340Docetaxel 278Bevacizumab 276Irinotecan 258Magnetic Resonance Spectroscopy 245Fluorouracil 229Dexamethasone 225Specimen Handling 223Capecitabine 218Rituximab 206Oxaliplatin 201Cytarabine 201Ipilimumab 198Temozolomide 197Biopsy 197fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 174Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Interventional × CBLB502 × Clear all
NCT01527136 2022-07-22

Entolimod in Treating Patients With Locally Advanced or Metastatic Solid Tumors That Cannot Be Removed By Surgery

Roswell Park Cancer Institute

Phase 1 Completed
25 enrolled
Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

NCT01728480 2013-12-11

Entolimod in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Receiving Cisplatin and Radiation Therapy

Roswell Park Cancer Institute

Phase 1 Withdrawn
Head & NeckOther

Squamous Cell Carcinoma of Head and Neck, Tongue Neoplasms, Mucositis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡